Document Detail


Monitoring activity of fibrinolytic agents. A therapeutic challenge.
MedLine Citation:
PMID:  6232847     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The recognition that thrombolytic therapy may be beneficial for coronary thrombolysis has led to an increased use of plasminogen activators in critically ill patients, sometimes with inadequate monitoring. This review delineates the components of the fibrinolytic system, describes mechanisms of fibrinolysis, and presents practical guidelines for monitoring the use of activators of the system.
Authors:
K E Shafer; S A Santoro; B E Sobel; A S Jaffe
Related Documents :
8187367 - High frequency qrs electrocardiography in the detection of reperfusion following thromb...
11153737 - Non-q-wave myocardial infarction following thrombolytic therapy: a comparison of outcom...
2662737 - Reperfusion, patency and reocclusion with anistreplase (apsac) in acute myocardial infa...
1797897 - Thrombolytic therapy soon after left heart catheterization--is it safe?
25324157 - Hospital admissions for acute myocardial infarction before and after implementation of ...
25457137 - Cardioversion of atrial fibrillation in a dog with structural heart disease using an es...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  76     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  1984 May 
Date Detail:
Created Date:  1984-06-05     Completed Date:  1984-06-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  879-86     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Coagulation Disorders / drug therapy
Drug Administration Schedule
Fibrin Fibrinogen Degradation Products / pharmacology
Fibrinolysin / antagonists & inhibitors,  physiology
Fibrinolysis / drug effects
Fibrinolytic Agents* / administration & dosage,  therapeutic use
Humans
Partial Thromboplastin Time
Plasminogen Activators / physiology
Prothrombin Time
Streptokinase / pharmacology
Thrombin Time
Urokinase-Type Plasminogen Activator / pharmacology
Grant Support
ID/Acronym/Agency:
AL-29608//PHS HHS; HL-17646/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.7/Fibrinolysin; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Suppressor cells in end-stage renal disease. Functional assays and monoclonal antibody analysis.
Next Document:  Effect of hemodialysis on left ventricular performance. Analysis of echocardiographic subsets.